真菌性角膜炎的药物治疗进展  

Current progression in pharmacotherapeutics of fungal keratitis

作　　者：瞿玲辉[1] 李良毛[1] 

机构地区：[1]解放军第181医院眼科中心,桂林541002

出　　处：《眼科研究》2010年第2期178-182,共5页Chinese Ophthalmic Research

基　　金：全军医学科研"十一五"计划基金资助(06G072)

摘　　要：真菌性角膜炎居中国感染性角膜炎的首位,已成为角膜盲的主要病因。随着对发病原因及机制的深入探讨,药物治疗取得了较大进展。为降低该病的致盲率,眼科医师应重视其治疗手段并提高其治疗效果。就抗真菌药物在眼科临床应用的研究进展进行综述。Fungal keratitis is the first common infectious corneal disease and has become the main cause of blindness in China. Along with the intensive explore for the pathogenic mechanisms, the significant progress has been achieved in the pharmacotherapeutics. For lowering its hlindnessrate,it is imperative to the study on increasing therapeutic option and enhancing therapeutic efficacy. This review summarizes the current advance in clinical use in ophthalmology of novel antifungal agents, including new azoles such as voriconazole and posaconazole,and echinocandins such as caspofungin and micafungin. This article also reviews the progress of administration routes for the management of recalcitrant fungal keratitis, including subconjunctival, interstromal,intracameral and intravitreal injection.

关 键 词：角膜炎 眼部感染 真菌 药物疗法 

分 类 号：R772.21[医药卫生—眼科]